Jacob Soumerai, Md

This study tested an experimental drug called belantamab mafodotin for people with two rare and aggressive types of lymphoma that had returned or not responded to prior treatments. The drug is designed to target and kill lymphoma cells directly. The goal was to see if the treatme…